Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
Objective:Epidemiologically, there is a strong relationship between BMI and blood pressure (BP) levels. We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m2; normal weight (BMI 30)].
Methods:In a randomized, double-blind, practice-based Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, 33 357 hypertensive participants, aged at least 55 years, were followed for an average of 4.9 years, for a primary outcome of fatal coronary heart disease or nonfatal myocardial infarction, and secondary outcomes of stroke, heart failure, combined cardiovascular disease, mortality, and renal failure.
Results:Of participants, 37.9% were overweight and 42.1% were obese at randomization. For each medication, BP control (
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Obesity Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Coronary Heart Disease | Eating Disorders & Weight Management | Epidemiology | Heart | Heart Attack | Heart Disease | Heart Failure | Hypertension | Lisinopril | Norvasc | Obesity | Renal Failure | Stroke